You searched for "age"
Clinical relevance of the anatomic classification of neovascular age-related macular degeneration
The author explains why an OCT-based classification of neovascular AMD is needed and how these neovascular subtypes may help to predict patients’ long-term visual outcome. Age-related macular degeneration (AMD) is a chronic and progressive neurodegenerative process involving the macula in...
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration
1 June 2015
| Jonathan Chan
|
EYE - Vitreo-Retinal
This is a sub-group study of double masked review of patients randomised to different dosages and treatment frequency compared between aflibercept and ranibizumab treatment. This is to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with...
Type 3 macular neovascularisation (MNV) due to age-related macular degeneration
3 October 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This paper systematically reviews and summarises the current knowledge on type 3 neovascularisation due to age-related macular degeneration which is defined as neovascularisation originating from the retinal deep capillary plexus that grows towards the outer retina often penetrating the level...
Autofluorescence patterns in subretinal haemorrhages associated with neovascular age-related macular degeneration
2 August 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The aim of this retrospective study was to describe the surgical results and fundus autofluorescence (FAF) patterns occurring in sub-macular haemorrhage (SMH) of duration <60 days in age-related macular degeneration (AMD). Notes from 39 eyes of 39 patients with SMH,...
Pilot trial of virtual reality to treat amblyopia beyond the age of seven years
A pilot double-blind randomised controlled trial is presented. Patients were required to be between seven and 38 years of age, have a diagnosis of anisometropic and / or strabismus unilateral amblyopia, visual acuity in the amblyopic eye between 0.3-1.0 LogMAR...More sensitive visual acuity test for age-related macular degeneration
1 October 2016
| Roger S Anderson (Prof), Nilpa Shah
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...
Exploring the potential of neurodegenerative disease screening within age-related eye disease research
3 August 2023
| Lauren R Hepworth
|
EYE - Neuro-ophthalmology
The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...
Aflibercept (AF) for age-related macular degeneration (ARMD): four-year outcomes of a ‘’treat-and-extend’ (T&E) regimen with exit-strategy
This is a retrospective observational study of 82 patients, between 2014 to 2016 from Switzerland of treatment-naive patients with nARMD, treated with AF, with specific T&E protocol without a loading phase and predefined exit criteria and patients were observed three...A trainee’s guide on how to prepare for the digital age of ophthalmology
6 April 2021
| Hari Kaneshayogan
|
EYE - General
As the pandemic rolls on, the past year has left many ophthalmic departments in disarray with ever-lengthening patient waiting-lists and increasing challenges in service delivery. Areas such as virtual clinics, telephone / video consultations have had to mature rapidly to...
Boosting key protein in eye cells could prevent age-related vision loss, international team finds
Increasing the levels of a key protein in the cells at the back of the eye could help protect against the leading cause of vision loss among older adults, finds a new discovery made by researchers from the UK, US, Germany and Australia.Age and gender impacts effectiveness of new gene therapy treatments for eye diseases, new study finds
14 February 2025
|
research, genetics, gene therapy, pathology, education, Adeno-Associated Virus, inflammation
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found. The University of Bristol-led study, published in Molecular Therapy, reveal how age and gender affects inflammation caused by gene...
New study uncovers key mechanism behind a common genetic cause of age-related visual loss
19 September 2024
|
Cornea / External Eye Disease
|
endothelial cells, age, vision loss, research, academic, new, genetics, genome, Fuchs Endothelial Corneal Dystrophy, FECD
A groundbreaking study has revealed important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, providing hope for future therapeutic developments, and finding implications for other neurological diseases. FECD is a common,...
